S&P 500   4,333.57 (+0.16%)
DOW   34,040.63 (-0.35%)
QQQ   339.93 (-0.34%)
AAPL   164.97 (+3.61%)
MSFT   297.93 (-0.64%)
FB   293.48 (-0.39%)
GOOGL   2,576.43 (-0.14%)
AMZN   2,764.11 (-1.03%)
TSLA   826.54 (-0.31%)
NVDA   215.65 (-1.73%)
BABA   110.42 (-1.23%)
NIO   19.91 (-5.68%)
AMD   101.29 (-1.28%)
CGC   6.83 (-0.29%)
MU   76.32 (-3.05%)
GE   89.26 (-0.71%)
T   24.37 (+1.04%)
F   19.09 (-2.35%)
DIS   134.67 (-0.55%)
AMC   13.73 (-5.44%)
PFE   53.81 (+0.82%)
ACB   3.74 (-1.32%)
BA   184.69 (-2.67%)
S&P 500   4,333.57 (+0.16%)
DOW   34,040.63 (-0.35%)
QQQ   339.93 (-0.34%)
AAPL   164.97 (+3.61%)
MSFT   297.93 (-0.64%)
FB   293.48 (-0.39%)
GOOGL   2,576.43 (-0.14%)
AMZN   2,764.11 (-1.03%)
TSLA   826.54 (-0.31%)
NVDA   215.65 (-1.73%)
BABA   110.42 (-1.23%)
NIO   19.91 (-5.68%)
AMD   101.29 (-1.28%)
CGC   6.83 (-0.29%)
MU   76.32 (-3.05%)
GE   89.26 (-0.71%)
T   24.37 (+1.04%)
F   19.09 (-2.35%)
DIS   134.67 (-0.55%)
AMC   13.73 (-5.44%)
PFE   53.81 (+0.82%)
ACB   3.74 (-1.32%)
BA   184.69 (-2.67%)
S&P 500   4,333.57 (+0.16%)
DOW   34,040.63 (-0.35%)
QQQ   339.93 (-0.34%)
AAPL   164.97 (+3.61%)
MSFT   297.93 (-0.64%)
FB   293.48 (-0.39%)
GOOGL   2,576.43 (-0.14%)
AMZN   2,764.11 (-1.03%)
TSLA   826.54 (-0.31%)
NVDA   215.65 (-1.73%)
BABA   110.42 (-1.23%)
NIO   19.91 (-5.68%)
AMD   101.29 (-1.28%)
CGC   6.83 (-0.29%)
MU   76.32 (-3.05%)
GE   89.26 (-0.71%)
T   24.37 (+1.04%)
F   19.09 (-2.35%)
DIS   134.67 (-0.55%)
AMC   13.73 (-5.44%)
PFE   53.81 (+0.82%)
ACB   3.74 (-1.32%)
BA   184.69 (-2.67%)
S&P 500   4,333.57 (+0.16%)
DOW   34,040.63 (-0.35%)
QQQ   339.93 (-0.34%)
AAPL   164.97 (+3.61%)
MSFT   297.93 (-0.64%)
FB   293.48 (-0.39%)
GOOGL   2,576.43 (-0.14%)
AMZN   2,764.11 (-1.03%)
TSLA   826.54 (-0.31%)
NVDA   215.65 (-1.73%)
BABA   110.42 (-1.23%)
NIO   19.91 (-5.68%)
AMD   101.29 (-1.28%)
CGC   6.83 (-0.29%)
MU   76.32 (-3.05%)
GE   89.26 (-0.71%)
T   24.37 (+1.04%)
F   19.09 (-2.35%)
DIS   134.67 (-0.55%)
AMC   13.73 (-5.44%)
PFE   53.81 (+0.82%)
ACB   3.74 (-1.32%)
BA   184.69 (-2.67%)
NASDAQ:ARTL

Artelo Biosciences News Headlines

$0.36
-0.01 (-1.89%)
(As of 01/28/2022 10:31 AM ET)
Add
Compare
Today's Range
$0.36
$0.36
50-Day Range
$0.37
$0.77
52-Week Range
$0.35
$3.67
Volume
2,800 shs
Average Volume
708,268 shs
Market Capitalization
$15.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.04
Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Artelo Biosciences Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARTL
News Sentiment

0.00

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARTL Articles
This Week

0

0

ARTL Articles
Average Week



Artelo Biosciences (NASDAQ:ARTL) News Headlines Today

SourceHeadline
MarketBeat logoArtelo Biosciences (NASDAQ:ARTL) Given "Buy" Rating at HC Wainwright
americanbankingnews.com - January 14 at 12:40 PM
MarketBeat logoArtelo Biosciences (NASDAQ:ARTL) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
americanbankingnews.com - January 14 at 11:34 AM
MarketBeat logoArtelo Biosciences (NASDAQ:ARTL) Releases Earnings Results, Misses Estimates By $0.02 EPS
americanbankingnews.com - January 13 at 7:28 AM
seekingalpha.com logoArtelo Biosciences GAAP EPS of -$0.08
seekingalpha.com - January 12 at 9:57 AM
finance.yahoo.com logoArtelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
finance.yahoo.com - January 12 at 9:57 AM
finance.yahoo.com logoArtelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
finance.yahoo.com - January 11 at 11:17 AM
MarketBeat logo Analysts Expect Artelo Biosciences, Inc. (NASDAQ:ARTL) Will Announce Earnings of -$0.06 Per Share
americanbankingnews.com - January 10 at 4:32 PM
finance.yahoo.com logoArtelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
finance.yahoo.com - January 10 at 2:02 PM
nasdaq.com logoArtelo Biosciences Inc Shares Close in on 52-Week Low - Market Mover
nasdaq.com - January 7 at 10:39 AM
msn.com logoIs Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?
msn.com - January 6 at 2:11 PM
nasdaq.com logoArtelo Biosciences Inc Shares Approach 52-Week Low - Market Mover
nasdaq.com - January 6 at 12:29 AM
finance.yahoo.com logoArtelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
finance.yahoo.com - November 29 at 1:29 PM
finance.yahoo.com logoWe Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully
finance.yahoo.com - November 2 at 10:55 AM
msn.com logoBRIEF-Artelo Biosciences Says On September 13, Received Notice From Nasdaq Indicating Co Is Not In Compliance With Certain Nasdaq Listing Rule
msn.com - September 17 at 7:10 PM
finance.yahoo.com logoArtelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 4:38 PM
seekingalpha.com logoArtelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript
seekingalpha.com - August 19 at 8:26 PM
seekingalpha.com logoArtelo Biosciences, Inc. 2021 Q3 - Results - Earnings Call Presentation
seekingalpha.com - August 18 at 6:31 PM
finance.yahoo.com logoArtelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
finance.yahoo.com - August 12 at 2:51 AM
finance.yahoo.com logoArtelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
finance.yahoo.com - August 4 at 9:48 AM
finance.yahoo.com logoLadenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
finance.yahoo.com - July 21 at 1:26 PM
finance.yahoo.com logoArtelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
finance.yahoo.com - July 12 at 8:42 AM
finance.yahoo.com logoArtelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
finance.yahoo.com - July 7 at 12:41 PM
finance.yahoo.com logoArtelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
finance.yahoo.com - June 22 at 9:31 AM
finance.yahoo.com logoArtelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th
finance.yahoo.com - June 2 at 11:30 AM
finance.yahoo.com logoArtelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021
finance.yahoo.com - May 6 at 8:30 AM
finance.yahoo.com logoKintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
finance.yahoo.com - May 4 at 8:33 AM
finance.yahoo.com logoWe're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely
finance.yahoo.com - April 20 at 10:46 AM
finance.yahoo.com logoArtelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
finance.yahoo.com - April 13 at 9:29 AM
finance.yahoo.com logoArtelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
finance.yahoo.com - April 12 at 1:16 PM
nasdaq.com logoWill Artelo Biosciences (NASDAQ:ARTL) Spend Its Cash Wisely?
nasdaq.com - April 8 at 8:22 AM
seekingalpha.com logoArtelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)
seekingalpha.com - March 25 at 10:34 AM
marketwatch.com logoArtelo Biosciences Inc. (NASDAQ: ARTL) Featured in Virtual Coverage of Investor Summit Group's Q1 Virtual Summit
marketwatch.com - March 23 at 8:59 AM
finance.yahoo.com logoArtelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
finance.yahoo.com - March 19 at 2:28 PM
finance.yahoo.com logoArtelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
finance.yahoo.com - March 19 at 2:28 PM
markets.businessinsider.com logoArtelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
markets.businessinsider.com - March 11 at 9:25 AM
finance.yahoo.com logoArtelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
finance.yahoo.com - March 11 at 9:25 AM
finance.yahoo.com logoArtelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
finance.yahoo.com - March 9 at 8:57 AM
finance.yahoo.com logoArtelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
finance.yahoo.com - March 2 at 8:49 AM
benzinga.com logoWhat To Know About Artelo Bio And Trinity College's Partnership For Cannabinoid And Cancer Research
benzinga.com - February 19 at 5:39 PM
finance.yahoo.com logoArtelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
finance.yahoo.com - February 17 at 9:54 AM
finance.yahoo.com logoArtelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
finance.yahoo.com - February 16 at 1:16 PM
benzinga.com logo12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com - February 12 at 1:47 PM
benzinga.com logoAnalyzing The Price Action In Artelo Biosciences Stock Today
benzinga.com - February 12 at 1:47 PM
finance.yahoo.com logoArtelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
finance.yahoo.com - February 8 at 8:40 AM
bloomberg.com logoArtelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of
bloomberg.com - February 4 at 10:53 PM
marketwatch.com logoThinking about buying stock in Artelo Biosciences, Vaxart, Inovio Pharmaceuticals, Vyne Therapeutics, or BioCryst Pharmaceuticals?
marketwatch.com - February 4 at 10:53 PM
finance.yahoo.com logoArtelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
finance.yahoo.com - February 2 at 1:37 PM
finance.yahoo.com logoArtelo Biosciences to Present at the LSX World Congress Virtual Conference
finance.yahoo.com - January 29 at 6:51 PM
finance.yahoo.com logoArtelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - January 14 at 3:41 PM
finance.yahoo.com logoArtelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
finance.yahoo.com - January 5 at 8:59 AM
Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.